Preclinical studies with TNF-α inhibitors, including infliximab and antibodies targeting transmembrane TNF-α, have demonstrated reduced tumor growth, metastasis, and synergistic effects with chemotherapy in BC models [97]. This evidence concerns the gene TNF and breast cancer.